Post-COVID rebound in invasive pneumococcal disease driven by resurgence of serotype 4 among American Indian individuals in the Southwest United States
Clicks: 3
ID: 316062
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #270 of 430 articles by views in The Journal of infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 430 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Incidence of invasive pneumococcal disease (IPD) in American Indian (AI) communities in the Southwest US declined during the COVID-19 pandemic. We estimated the burden and serotype distribution of IPD in the same communities in 2022-24. METHODS: We conducted active, laboratory-based surveillance for IPD in the Navajo Nation and White Mountain Apache Tribal (WMAT) lands. Isolates were collected and serotyped. Annual incidence rates were calculated and serotype distribution was estimated. The proportion of serotypes covered by available pneumococcal conjugate vaccines (PCV20 and PCV21) were estimated and compared by age group using McNemar's Chi-squared or Exact McNemar tests, as appropriate. RESULTS: IPD rates increased from 2022 to 2024 to pre-pandemic levels; from 45.9 to 62.1 per 100,000 in the Navajo Nation and 52.9 to 84.4 in the WMAT lands. Among adults in the Navajo Nation, serotype 4 accounted for 28.5% of cases and occurred primarily among younger unvaccinated males. The proportion of cases covered by PCV21 was lower than PCV20 for adults 18-49 years (53.2% vs 77.3%; p<0.001) but higher for adults ≥65 years (82.5% vs 65.1%; p=0.03). In the WMAT lands, no cases of serotype 4 were identified; the proportion of cases covered by PCV21 was the same or higher than for PCV20 across age groups. CONCLUSIONS: In two AI communities in the Southwest, IPD rates returned to pre-pandemic levels. In the Navajo Nation, the increase was driven by serotype 4 IPD among younger male unvaccinated adults. These findings can inform vaccine recommendations and highlight the value of surveillance.
| Reference Key |
openalex_W7163717905
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Catherine G. Sutcliffe, Victoria M. Sergent, Del Yazzie, George Brasinikas, Loretta Christensen, Matthew Clark, Wanda Cowboy, Sheri L. Dixon, Lindsay R. Grant, Marcella Harker-Jones, Chloe Hurley, Jonathan V. Iralu, James McAuley, Karen Miernyk, Pierrette Montanez, Amy Rice, Eugene Romancito, Charis Salabye, Brenna Simons-Petrusa, Joyselynn Pitalua, Valerie Tenequer, Polly Thompson, Minnie Tsingine, Dan VanDeRiet, Robert Weatherholtz, Mathuram Santosham, Laura L Hammitt |
| Journal | The Journal of infectious diseases |
| Year | 2026 |
| DOI |
10.1093/infdis/jiag285
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.